JP7093473B2 - 製造性及び溶出性に優れた小型錠剤 - Google Patents

製造性及び溶出性に優れた小型錠剤 Download PDF

Info

Publication number
JP7093473B2
JP7093473B2 JP2021564057A JP2021564057A JP7093473B2 JP 7093473 B2 JP7093473 B2 JP 7093473B2 JP 2021564057 A JP2021564057 A JP 2021564057A JP 2021564057 A JP2021564057 A JP 2021564057A JP 7093473 B2 JP7093473 B2 JP 7093473B2
Authority
JP
Japan
Prior art keywords
imeglimin
hydrochloride
less
tablet according
tablet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021564057A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021117861A5 (https=
JPWO2021117861A1 (https=
Inventor
寛樹 錠
隆 清水
陽平 西田
太一 松本
拓海 淺田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma Co Ltd
Original Assignee
Sumitomo Dainippon Pharma Co Ltd
Sumitomo Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Dainippon Pharma Co Ltd, Sumitomo Pharma Co Ltd filed Critical Sumitomo Dainippon Pharma Co Ltd
Publication of JPWO2021117861A1 publication Critical patent/JPWO2021117861A1/ja
Publication of JPWO2021117861A5 publication Critical patent/JPWO2021117861A5/ja
Priority to JP2022097803A priority Critical patent/JP7671265B2/ja
Application granted granted Critical
Publication of JP7093473B2 publication Critical patent/JP7093473B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Semiconductor Lasers (AREA)
JP2021564057A 2019-12-13 2020-12-11 製造性及び溶出性に優れた小型錠剤 Active JP7093473B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022097803A JP7671265B2 (ja) 2019-12-13 2022-06-17 製造性及び溶出性に優れた小型錠剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019225718 2019-12-13
JP2019225718 2019-12-13
PCT/JP2020/046253 WO2021117861A1 (ja) 2019-12-13 2020-12-11 製造性及び溶出性に優れた小型錠剤

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022097803A Division JP7671265B2 (ja) 2019-12-13 2022-06-17 製造性及び溶出性に優れた小型錠剤

Publications (3)

Publication Number Publication Date
JPWO2021117861A1 JPWO2021117861A1 (https=) 2021-06-17
JPWO2021117861A5 JPWO2021117861A5 (https=) 2022-06-02
JP7093473B2 true JP7093473B2 (ja) 2022-06-29

Family

ID=76330003

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021564057A Active JP7093473B2 (ja) 2019-12-13 2020-12-11 製造性及び溶出性に優れた小型錠剤
JP2022097803A Active JP7671265B2 (ja) 2019-12-13 2022-06-17 製造性及び溶出性に優れた小型錠剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022097803A Active JP7671265B2 (ja) 2019-12-13 2022-06-17 製造性及び溶出性に優れた小型錠剤

Country Status (5)

Country Link
JP (2) JP7093473B2 (https=)
KR (1) KR20220113942A (https=)
CN (1) CN114945370A (https=)
TW (1) TW202135826A (https=)
WO (1) WO2021117861A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116440075B (zh) * 2023-06-01 2025-05-06 苏州中化药品工业有限公司 一种干混悬剂及其制备方法

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009523139A (ja) 2006-01-13 2009-06-18 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング トリアジン誘導体およびインスリン分泌促進剤の組合せ
JP2009523141A (ja) 2006-01-13 2009-06-18 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング トリアジン誘導体およびＨＭＧ−ＣｏＡレダクターゼ阻害剤の組合せ
JP2012511521A (ja) 2008-12-12 2012-05-24 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング インスリンとトリアジンの組合せ及び糖尿病を治療するためのその使用
WO2014038593A2 (ja) 2012-09-05 2014-03-13 テイカ製薬株式会社 口腔内速崩壊性錠剤用造粒物
JP2017141289A (ja) 2012-01-06 2017-08-17 エルセリクス セラピューティクス インコーポレイテッド ビグアナイド組成物および代謝障害を治療する方法
WO2017170858A1 (ja) 2016-03-31 2017-10-05 大日本住友製薬株式会社 溶出性に優れた経口製剤
JP2018154586A (ja) 2017-03-17 2018-10-04 ライオン株式会社 錠剤

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI436768B (zh) 2010-06-09 2014-05-11 Poxel 第２型糖尿病之治療
CA3103324A1 (en) * 2018-06-14 2019-12-19 Poxel Film-coated tablet comprising a triazine derivative for use in the treatment of diabetes

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009523139A (ja) 2006-01-13 2009-06-18 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング トリアジン誘導体およびインスリン分泌促進剤の組合せ
JP2009523141A (ja) 2006-01-13 2009-06-18 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング トリアジン誘導体およびＨＭＧ−ＣｏＡレダクターゼ阻害剤の組合せ
JP2012511521A (ja) 2008-12-12 2012-05-24 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング インスリンとトリアジンの組合せ及び糖尿病を治療するためのその使用
JP2017141289A (ja) 2012-01-06 2017-08-17 エルセリクス セラピューティクス インコーポレイテッド ビグアナイド組成物および代謝障害を治療する方法
WO2014038593A2 (ja) 2012-09-05 2014-03-13 テイカ製薬株式会社 口腔内速崩壊性錠剤用造粒物
WO2017170858A1 (ja) 2016-03-31 2017-10-05 大日本住友製薬株式会社 溶出性に優れた経口製剤
JP2018154586A (ja) 2017-03-17 2018-10-04 ライオン株式会社 錠剤

Also Published As

Publication number Publication date
KR20220113942A (ko) 2022-08-17
JP2022123069A (ja) 2022-08-23
JPWO2021117861A1 (https=) 2021-06-17
TW202135826A (zh) 2021-10-01
WO2021117861A1 (ja) 2021-06-17
JP7671265B2 (ja) 2025-05-01
CN114945370A (zh) 2022-08-26

Similar Documents

Publication Publication Date Title
KR100762847B1 (ko) 멀티플 유닛 타입 서방성 경구 제제 및 그 제조방법
US6610326B2 (en) Divalproex sodium tablets
TWI468191B (zh) 有機化合物之調配物
JP5278708B2 (ja) ナテグリニド含有親水性医薬製剤
CN104220068B (zh) 包含奥美沙坦酯和罗苏伐他汀或其盐的药物组合物
WO2006070781A1 (ja) 塩基性薬物又はその塩を含有するマトリックス型徐放性製剤およびその製造方法
WO2000009133A1 (fr) Preparations orales, a liberation prolongee, a base de chlorhydrate de fasudil
WO2001034147A1 (en) Oral solid preparation
JP2002531395A (ja) 医薬合剤
JP2014040475A (ja) 新規製剤
CA3224531A1 (en) A pharmaceutical composition comprising combination of sitagliptin and empagliflozin
WO2013114389A1 (en) Process for preparing solid oral formulations comprising low dose of entecavir
JP7093473B2 (ja) 製造性及び溶出性に優れた小型錠剤
JP4567640B2 (ja) 小型化塩酸サルポグレラート経口投与製剤
WO2013061338A1 (en) Pharmaceutical compositions of silodosin
KR100780479B1 (ko) 이부딜라스트 함유 경구용 제제 및 이의 제조방법
HK40074201A (en) Small-sized tablet having excellent producibility and elution properties
KR20220015437A (ko) 피리미디닐아미노-피라졸 화합물의 변형 방출 제제, 및 치료 방법
WO2014096983A1 (en) Stable pharmaceutical compositions of saxagliptin or salts thereof
WO2013054178A2 (en) Extended release pharmaceutical compositions containing carmabazepine
JP5563371B2 (ja) クエチアピンフマル酸塩含有経口用錠剤
EP2233131A1 (en) Pharmaceutical composition containing levodopa, entacapone and carbidopa
KR102065090B1 (ko) 레베티라세탐 또는 이의 약제학적으로 허용되는 염을 함유하는 서방성 제제 및 이의 제조방법
WO2024024865A1 (ja) レボドパ持続性製剤
EA029709B1 (ru) Твердая пероральная лекарственная форма, содержащая декскетопрофен и трамадол, и способ ее изготовления

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220405

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220405

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20220405

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220524

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220617

R150 Certificate of patent or registration of utility model

Ref document number: 7093473

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150